CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

Related Keywords

China ,Beijing ,United States ,Rockville ,California ,San Francisco ,Rui Zhang ,Bristol Myers Squibb ,Pharmaceuticals China Co Ltd ,China National Medical Products Administration ,Company Clinical Trial Application ,Pharmaceuticals Inc ,Osage University Partners ,Nasdaq ,Multiple Myeloma ,Clinical Trial Application ,Recommended Phase ,Chief Executive Officer ,Cleave Therapeutics ,Marcus Ventures ,Astellas Venture Management ,Osage University ,Greater China ,Private Securities Litigation Reform Act ,Casi Pharmaceuticals ,Nc ,